Id
|
lncRNAs
|
Author
|
Year
|
Country
|
Duration of research
|
Number of Patients (high/low)
|
Sum of Patients
|
Expression in Tumor
|
Internal reference
|
Method
|
Cut-off
|
Quality Score
|
Follow-up (Month)
|
Sample
|
Outcome
|
---|
1
|
TMED11P
|
Zhenfei Zhu
|
2016
|
China
|
2007–2013
|
21/57
|
78
|
Down-regulation
|
U6
|
qRT-PCR
|
Median
|
7
|
60
|
Tissue
|
OS
|
2
|
LOC389641
|
Shangyou Zheng
|
2015
|
China
|
2008–2015
|
53/53
|
106
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
72
|
Tissue
|
OS
|
6
|
HMlincRNA717
|
X.L.SUN
|
2016
|
China
|
2005–2011
|
74/76
|
150
|
Down-regulation
|
U6
|
qRT-PCR
|
Median
|
7
|
70
|
Tissue
|
OS
|
7
|
ATB
|
Shibin Qu
|
2015
|
China
|
No
|
75/75
|
150
|
Down-regulation
|
β-Actin
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
8
|
CCDC26
|
Wei Peng
|
2016
|
China
|
2011–2015
|
20/20
|
40
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
7
|
60
|
Tissue
|
OS
|
9
|
uc.345
|
Chao Liu
|
2016
|
China
|
2011–2013
|
68/35
|
103
|
Up-regulation
|
RNU6B
|
qRT-PCR
|
Median
|
6
|
50
|
Tissue
|
OS
|
11
|
Linc-pint
|
Le Li
|
2016
|
China
|
2008–2011
|
28/23
|
51
|
Down-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
60
|
Plasma
|
OS
|
17
|
AFAP1-AS1
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
17
|
UCA1
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
17
|
ENSG00000218510
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Down-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
17
|
CRNDE
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
17
|
NR_036488
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
17
|
ENSG00000244649
|
Xue-Liang Fu
|
2016
|
China
|
2012–2014
|
40/40
|
80
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
50–60
|
Tissue
|
OS
|
18
|
UCA1
|
Ping Chen
|
2016
|
China
|
2006–2009
|
64/64
|
128
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Mean
|
8
|
60
|
Tissue
|
OS
|
23
|
HOTTIP-005
|
Yingxue Wang
|
2015
|
China
|
2006–2014
|
118/26
|
144
|
Up-regulation
|
GAPDH & β-Actin
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
23
|
XLOC_006390
|
Yingxue Wang
|
2015
|
China
|
2006–2014
|
110/34
|
144
|
Up-regulation
|
GAPDH & β-Actin
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
23
|
RP11-567G11.1
|
Yingxue Wang
|
2015
|
China
|
2006–2014
|
96/48
|
144
|
Up-regulation
|
GAPDH & β-Actin
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
24
|
MALAT1
|
Er-Jun Pang
|
2014
|
China
|
No
|
63/63
|
126
|
Up-regulation
|
β-Actin
|
qRT-PCR
|
Median
|
7
|
60
|
Tissue
|
OS
|
38
|
ENST00000480739
|
Y-W Sun
|
2014
|
China
|
No
|
20/15
|
35
|
Down-regulation
|
β-Actin
|
qRT-PCR
|
Median
|
8
|
30
|
Tissue
|
OS
|
39
|
HULC
|
Wei Peng
|
2014
|
China
|
2006–2010
|
212/92
|
304
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
No
|
7
|
60
|
Tissue
|
OS
|
40
|
MALAT1
|
Jiang-Hua Liu
|
2014
|
China
|
2010–2011
|
26/19
|
45
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Mean
|
8
|
40
|
Tissue
|
DSS
|
41
|
BC008363
|
Jiao Li
|
2014
|
China
|
2009- 2010
|
17/13
|
30
|
Down-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
30
|
Tissue
|
OS
|
43
|
LOC285194
|
Yue-Chao Ding
|
2014
|
China
|
2004–2009
|
45/40
|
85
|
Down-regulation
|
GAPDH
|
qRT-PCR
|
Mean
|
6
|
60
|
Tissue
| |
50
|
C/EBPb
|
Chen-Song Huang
|
2017
|
China
|
2008–2013
|
54/29
|
83
|
Up-regulation
|
NO
|
qRT-PCR
|
Mean
|
7
|
100
|
Tissue
|
OS/DFS
|
50
|
LINC01133
|
Chen-Song Huang
|
2018
|
China
|
2015–2017
|
88/89
|
177
|
Up-regulation
|
NO
|
qRT-PCR
|
Mean
|
8
|
100
|
Tissue
|
OS/DFS
|
59
|
DUXAP8
|
Yifan Lian
|
2018
|
China
|
2007–2012
|
29/29
|
58
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
median
|
7
|
60
|
Tissue
|
OS
|
67
|
CASC2
|
Yaqun Yu
|
2017
|
China
|
No
|
56/54
|
110
|
Down-regulated
|
RNU6B
|
qRT-PCR
|
Median
|
7
|
48
|
Tissue
|
OS
|
76
|
DANCR
|
Lei Chen
|
2018
|
China
|
No
|
86/120
|
206
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Mean
|
8
|
72
|
Tissue
|
OS/PFS
|
83
|
LINC00346
|
Wan-Xin Peng
|
2019
|
China
|
No
|
46/131
|
177
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
No
|
4
|
80
|
Tissue
|
OS
|
103
|
XIST
|
Wei Wei
|
2017
|
China
|
No
|
32/32
|
64
|
Up-regulation
|
RNU6B
|
qRT-PCR
|
Median
|
8
|
30
|
Tissue
|
OS
|
109
|
ABHD11-AS1
|
X. QIAO
|
2018
|
China
|
2010–2013
|
72/75
|
147
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
No
|
8
|
60
|
Tissue
|
OS
|
112
|
DLEU1
|
Song Gao
|
2018
|
China
|
2012–2017
|
39/23
|
62
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
114
|
FEZF1‐AS1
|
Zheng‐Lin Ou
|
2019
|
China
|
No
|
28/28
|
56
|
Up-regulation
|
RNU6B
|
qRT-PCR
|
Median
|
7
|
60
|
Tissue
|
OS
|
125
|
lnc-PCTST
|
Yandong Wang
|
2018
|
China
|
2015–2016
|
24/24
|
48
|
Down-regulated
|
β-Actin
|
qRT-PCR
|
Median
|
6
|
20
|
Tissue
|
OS
|
126
|
MACC1-AS1
|
Chen Qi
|
2019
|
China
|
No
|
49/49
|
98
|
Up-regulation
|
β-Actin
|
qRT-PCR
|
No
|
6
|
100
|
Tissue
|
OS
|
136
|
XLOC_000647
|
Hao Hu
|
2018
|
China
|
2015–2016
|
24/24
|
48
|
Down-regulated
|
β-Actin
|
qRT-PCR
|
Median
|
7
|
20
|
Tissue
|
OS
|
144
|
HOTTIP
|
Ozkan Balcin
|
2018
|
Turkey
|
2006–2014
|
61/39
|
100
|
Up-regulation
|
GAPDH
|
Q qRT-PCR
|
No
|
7
|
46
|
Tissue
|
OS
|
152
|
MSC-AS1
|
Yunpeng Sun
|
2019
|
China
|
No
|
23/22
|
45
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
6
|
36
|
Tissue
|
OS
|
159
|
Sox2ot
|
Zhonghu Li
|
2018
|
China
|
2012–2016
|
31/30
|
61
|
Up-regulation
|
NO
|
qRT-PCR
|
Median
|
8
|
50
|
Blood
|
OS
|
162
|
SPRY4-IT1
|
Yue Yaoa
|
2018
|
China
|
2011–2012
|
26/20
|
46
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
No
|
7
|
60
|
Tissue
|
OS
|
169
|
GSTM3TV2
|
Guangbing Xiong
|
2019
|
China
|
No
|
100/80
|
180
|
Up-regulation
|
GAPDH & U7
|
qRT-PCR
|
No
|
8
|
80
|
Tissue
|
OS
|
172
|
SNHG15
|
X.-B. GUO
|
2018
|
China
|
No
|
82/89
|
171
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
60
|
Tissue
|
OS
|
185
|
HULC
|
Zheng-Lin Ou
|
2019
|
China
|
2012–2014
|
NO
|
60
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
8
|
40
|
Tissue
|
OS
|
186
|
lncRNA-UFC1
|
Peng Liu
|
2019
|
China
|
2012–2015
|
19/29
|
48
|
Up-regulation
|
U6
|
qRT-PCR
|
Mean
|
8
|
60
|
Serum
|
OS
|
187
|
FOXP4-AS1
|
Xiao-Guang Liu
|
2019
|
China
|
No
|
NO
|
112
|
Up-regulation
|
NO
|
NO
|
Median
|
4
|
50
|
Tissue
|
OS
|
188
|
PLACT1
|
Xiaofan Ren
|
2020
|
China
|
2008–2018
|
83/83
|
166
|
Up-regulation
|
NO
|
NO
|
Median
|
7
|
60
|
Tissue
|
OS
|
189
|
ENSG00000254041.1
|
Bo Chen
|
2020
|
China
|
2013–2014
|
35/35
|
70
|
Up-regulation
|
GAPDH
|
qRT-PCR
|
Median
|
4
|
50
|
Tissue
|
OS
|
- OS overall survival, RFS recurrence-free survival, DFS disease free survival, DSS disease specific survival, PFS prognosis free survival, TMED11P trafficking protein 11, pseudogene, lncRNA-ATB long non-coding RNA-activated by transforming growth factor β, AFAP1-AS1 actin filament-associated protein 1 antisense RNA 1, UCA1 urothelial carcinoma associated 1 RNA, CRNDE Colorectal neoplasia differentially expressed, HOTTIP HOXA transcript at the distal tip, Malat1 metastasis associated lung adenocarcinoma transcript 1, CASC2 Cancer susceptibility candidate 2, DANCR Differentiation antagonizing non-protein coding RNA, XIST X-inactive specific transcript, SNHG16 small nucleolar RNA host gene 16, HULC Highly up‐regulated in liver cancer, qRT-PCR quantitative real-time polymerase chain reaction, NA not applicable